T-Ray Science, TeraView Enter Into Sub-Licensing Agreement
As per the terms of the sub-licensing agreement, T-Ray Science is expected to collect royalties on the sales of this product and any other products that utilise CW
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).